Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Subcision + platelet-rich plasma is a combination procedural and biological therapy investigated by Assiut University for the treatment of atrophic post-acne scars. The treatment involves subcision, a surgical technique using an 18-gauge blunt cannula to release fibrotic strands under the skin, followed by the intradermal injection of autologous platelet-rich plasma (PRP). PRP acts as a concentrated source of growth factors, including platelet-derived growth factor (PDGF), transforming growth factor-beta (TGF-β), and vascular endothelial growth factor (VEGF), which promote fibroblast proliferation, collagen neogenesis, and tissue remodeling. This combination approach aims to provide superior cosmetic outcomes compared to subcision alone by addressing both the mechanical tethering of scars and the underlying dermal volume loss.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on subcision + platelet-rich plasma.